Abstract:
INTRODUCTION:Combination of glibenclamide (glyburide in the U.S.) and metformin hydrochloride simultaneously addresses two different but complimentary mechanisms to improve glycemic control in type 2 diabetes. AREAS COVERED:The pharmacokinetics, efficacy, and side effect profile of the oral combination of glibenclamide-metformin are reviewed. EXPERT OPINION:Those patients, uncontrolled with single oral agent sulfonylurea or metformin alone, benefit from combination glibenclamide-metformin. There is improvement in fasting plasma glucose, HbA(1C), and post-prandial glucose control, and patients are more likely to achieve a HbA(1C) < 7%. Initiation should be started at the lowest doses and titrated to get the desired effect. Combination therapy allows for reduced pill burden while treating a multifactorial disease by two different mechanisms. Practitioners should be cognizant of risks of hypoglycemia and the theoretical potential for lactic acidosis in the elderly and those with renal impairment. We caution the use of glibenclamide-metformin in patients at risk for cardiovascular disease. Therapy should be individualized, but overall, combination of glibenclamide-metformin should be considered in patients, without renal or cardiovascular impairment, who are not controlled on monotherapy alone. Alternatively, practitioners may want to weigh the efficacy and safety of available dipeptidyl-peptidase-4 inhibitor-metformin combinations to those of glibenclamide-metformin when considering combination therapy.
journal_name
Expert Opin Pharmacotherjournal_title
Expert opinion on pharmacotherapyauthors
Lamos EM,Stein SA,Davis SNdoi
10.1517/14656566.2012.738196subject
Has Abstractpub_date
2012-12-01 00:00:00pages
2545-54issue
17eissn
1465-6566issn
1744-7666journal_volume
13pub_type
杂志文章,评审abstract:INTRODUCTION:Despite intensified insulin treatment, many persons with type 1 diabetes (T1D) do not achieve glycemic and metabolic targets. Consequently, non-insulin chemical therapies that improve glycemic control and metabolic parameters without increasing the risk of adverse events (including hypoglycemia) are of int...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1483339
更新日期:2018-06-01 00:00:00
abstract::One of the most significant advances of the last decade has been the development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. A large series of randomised, controlled clinical trials of these agents have shown a significant reduction in ischaemic events, not only in acute coronary syndrome patients, but...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.5.2.335
更新日期:2004-02-01 00:00:00
abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1774556
更新日期:2020-09-01 00:00:00
abstract:INTRODUCTION:Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder, whose medical and socioeconomic burden as one of the main causes of morbidity and mortality is increasing worldwide. COPD pathophysiology includes chronic airway/lung inflammation and progressive airflow limitation. Therefore, ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2015.1070826
更新日期:2015-01-01 00:00:00
abstract::The incidence of nucleoside analogue-related lactic acidosis has been estimated in 0.57 - 8.5 cases/1000 person years of antiretroviral therapy. The onset of lactic acidosis is usually insidious and patients complain of nausea, vomiting, abdominal pain, fatigue and weight loss. When lactate levels are high enough, a c...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.8.1321
更新日期:2003-08-01 00:00:00
abstract::Negative symptoms are core features of schizophrenia that respond poorly to first-generation antipsychotics and present a major obstacle in rehabilitation. Patients may be somewhat more responsive to clozapine and second-generation antipsychotics but even then, considerable impairment remains. This paper reviews the u...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.5.10.2053
更新日期:2004-10-01 00:00:00
abstract:INTRODUCTION:Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia. The management of gout implies both the treatment of flares and the treatment of hyperuricaemia itself. Recent improvement in the understanding of the...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2017.1351945
更新日期:2017-08-01 00:00:00
abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2014.889116
更新日期:2014-04-01 00:00:00
abstract::Motor fluctuations are common and distressing for patients with advanced Parkinson's disease. Subcutaneous apomorphine injections can be an extremely valuable adjunctive therapy. In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.16.2799
更新日期:2007-11-01 00:00:00
abstract:INTRODUCTION:Atherosclerosis is frequently caused by clot blockage of the coronary or peripheral arteries, and may lead to myocardial infarction (MI) or peripheral arterial disease (PAD). Despite advancements in management of atherosclerosis, mortality and ischemic rates remain high. Vorapaxar is a protease activated r...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2015.1099629
更新日期:2015-01-01 00:00:00
abstract:INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2014.972364
更新日期:2014-12-01 00:00:00
abstract::There has been an increase in the incidence and prevalence of gout in the past several decades. A distinction needs to be made between the treatment of gout as an acute inflammatory disease and the lowering of the serum urate (SU) levels into a normal range. Treating acute gout attacks alone is not sufficient to preve...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560902950742
更新日期:2009-06-01 00:00:00
abstract::The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF). Although the benefits observed with such drugs are viewed as a class effect, theoretically, carvedilol might ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.5.6.1359
更新日期:2004-06-01 00:00:00
abstract:INTRODUCTION:Hypertension is highly prevalent in patients with end-stage kidney disease on hemodialysis and is often not well controlled. Blood pressure (BP) levels before and after hemodialysis have a U-shaped relationship with cardiovascular and all-cause mortality. Although antihypertensive drugs are recommended for...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1746272
更新日期:2020-07-01 00:00:00
abstract::Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2019.1623879
更新日期:2019-08-01 00:00:00
abstract:BACKGROUND:Acute pulmonary embolism (PE) is a life-threatening condition that has been treated with anticoagulation for almost 50 years. OBJECTIVES:To review the current treatment options for PE and discuss recently published new features. METHODS:We reviewed literature involving the treatment strategies for venous t...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560902911470
更新日期:2009-05-01 00:00:00
abstract::Childhood nephrotic syndrome (NS) is a distressing chronic renal disorder with potentially life threatening complications. Over 80% of cases in children are due to minimal change disease and the majority will respond to corticosteroid therapy. Steroid-sensitive NS is considered a relatively benign condition, since pro...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.3.5.513
更新日期:2002-05-01 00:00:00
abstract::Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2019.1622090
更新日期:2019-09-01 00:00:00
abstract::Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in th...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.1.4.841
更新日期:2000-05-01 00:00:00
abstract:INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2016.1217990
更新日期:2016-09-01 00:00:00
abstract::Overactive bladder (OAB) is a common problem. Affected individuals suffer decreased quality of life and productivity. The mainstay of pharmacological treatment of OAB is antimuscarinic agents. Tolterodine was the first antimuscarinic drug designed specifically for treating OAB. Compared with the immediate-release (IR)...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560903167965
更新日期:2009-09-01 00:00:00
abstract::The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia. New information continues to emerge on the impact of olanzapine on schizophrenia and on aspects of...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.6.12.2077
更新日期:2005-10-01 00:00:00
abstract::Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.2.203
更新日期:2007-02-01 00:00:00
abstract:INTRODUCTION:Bradykinin-mediated angioedema is characterized by subcutaneous and/or submucosal edema formation without wheals and pruritus. It is linked to bradykinin-enhanced vascular permeability and, therefore, it does not respond to conventional measures, but requires specific therapy. AREAS COVERED:This summary b...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2013.778826
更新日期:2013-04-01 00:00:00
abstract:OBJECTIVE:Injection diclofenac sodium available at present as a 3-ml formulation is administered intragluteally. Standard needles may not reach the gluteus maximus muscle in many cases, especially in obese patients. Alternative sites like the deltoid have been suggested to be more suitable for these patients. Diclofena...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656560902732066
更新日期:2009-03-01 00:00:00
abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.1.7.1353
更新日期:2000-12-01 00:00:00
abstract::Genomic variations influencing response to pharmacotherapy of pain are under investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules important for pharmacotherapy are discussed. Drug metabolising enzymes represent a further major target of ongoing research in order to identify assoc...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.14.2235
更新日期:2007-10-01 00:00:00
abstract::The American Heart Association annual meeting must be one of the largest scientific gatherings, attracting over 30,000 delegates. The meeting at the end of last year was held in Atlanta, USA, the 2000 meeting will be in New Orleans, USA. The following highlights represent my own interests. ...
journal_title:Expert opinion on pharmacotherapy
pub_type:
doi:10.1517/14656566.1.3.581
更新日期:2000-03-01 00:00:00
abstract::Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.5.779
更新日期:2003-05-01 00:00:00
abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.671296
更新日期:2012-04-01 00:00:00